Showing results (1161-1170 of 1,198) with videos related to
Sort By:
Pageof 120
Human Gene Therapy. Clinical Development|October 4, 2018
Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 MiceChunjuan Song, Thomas J Conlon, Wen-Tao Deng, et al.JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.Journal of Bone Oncology|April 18, 2017
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGPeyman Hadji, Matti S Aapro, Jean-Jacques Body, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone MicroenvironmentClaudia Tulotta, Diane V Lefley, Katy Freeman, et al.Molecular Therapy. Methods & Clinical Development|November 25, 2021
Erratum: Voluntary wheel running complements microdystrophin gene therapy to improve muscle function in mdx miceShelby E Hamm, Daniel D Fathalikhani, Katherine E Bukovec, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.Molecular Therapy. Methods & Clinical Development|April 14, 2021
Voluntary wheel running complements microdystrophin gene therapy to improve muscle function in mdx miceShelby E Hamm, Daniel D Fathalikhani, Katherine E Bukovec, et al.Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.Pageof 120